A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy

Hugh D Allen, Kevin M Flanigan, Philip T Thrush, Igor Dvorchik, Han Yin, Charles Canter, Anne M Connolly, Mark Parrish, Craig M McDonald, Elizabeth Braunlin, Steven D Colan, John Day, Basil Darras, Jerry R Mendell, Hugh D Allen, Kevin M Flanigan, Philip T Thrush, Igor Dvorchik, Han Yin, Charles Canter, Anne M Connolly, Mark Parrish, Craig M McDonald, Elizabeth Braunlin, Steven D Colan, John Day, Basil Darras, Jerry R Mendell

Abstract

Objectives: This study sought to compare the effectiveness and safety of an angiotensin converting enzyme inhibitor (ACE-I) (lisinopril) vs. an angiotensin receptor blocker (ARB) (losartan) for the treatment of cardiomyopathy (CM) in boys with Duchenne muscular dystrophy (DMD).

Background: Development of CM is universal in boys with DMD. ACE-I and ARB have both been suggested as effective treatment options. ARBs have been associated with skeletal muscle regeneration in a mouse model of DMD. The question of which, if either, is more effective for CM treatment in DMD remains. The purpose of this multicenter double-blind prospective study was to compare efficacy and safety of lisinopril versus losartan in the treatment of newly diagnosed CM in boys with DMD.

Methods: Echocardiographic technician inter- and intraobserver variability were tested on 2 separate days on 2 different boys with DMD CM. Results were compared with paired t-testing. Twenty-two boys with newly diagnosed DMD CM (echocardiographic ejection fraction (EF) 10% EF drop. Three boys in the aCE-I group had 3 visits, due to study funding termination. Two were withdrawn because of low EF. All their data are included in the analysis for as long as they remained in the study. Mean EF's were similar at baseline (47.5%- ACE-I, 48.4%- ARB). After 1 year each group significantly improved to 54.6% and 55.2% respectively (p=.02). There was no difference between the 2 treatment groups at 1 year.

Conclusions: Inter-observer and intra-observer reliability studies showed no differences between echocardiographers on serial examinations. EF improved equally in the two groups. There is no therapeutic difference in EF improvement between lisinopril and losartan over the one-year duration for treatment of boys with DMD-related CM.

Trial registration: ClinicalTrials.gov NCT01982695.

Figures

Enrollment, Allocation, Follow-up, and Analysis of Trial…
Enrollment, Allocation, Follow-up, and Analysis of Trial Participants
Serial data for both groups. Lisinopril in…
Serial data for both groups. Lisinopril in red, losartan in blue.
EF is shown on the ordinate and time on the abscissa.

References

    1. Allen HD, Mendell JR, and Hoffman TM. The Heart in Muscular Dystrophies; Chapter 60 in Moss and Adams’ Heart Disease in Infants, Children, and Adolescents, Including the Fetus and Young Adult, 7th Ed. Phildadelphia, Wolters Kluwer/Lippincott Williams and Wilkins, 2008.
    1. Viollet, Laurence PhD, Thrush, Philip T. MD, Flanigan ,Kevin M. MD, Mendell, Jerry R. MD, Allen, Hugh D MD. “Effects of Angiotensin-Converting Enzyme Inhibitors and/or Beta Blockers on the Cardiomyopathy in Duchenne Muscular Dystrophy”. Am J Cardiol 2012; 110(1):98-102. Epub ahead of print, 3/29/12.
    1. Allen HD, Thrush PT, Hoffman TM, Flanigan KM, Mendell JT: Cardiac Management in Neuromuscular Disease. 2012; Phys Med Rehabil Clin N Am 23:855-68.
    1. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Becane HM. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005; 45: 855-857.
    1. Hor KN, Wanasapura J, Markham LW, et al. Circumferential Strain Analysis Identifies Strata of Cardiomyopathy in Duchenne Muscular Dystrophy. A Cardiac Magnetic Resnonance Tagging Study. J Am Coll Cardiol 2009; 53: 1204-10.
    1. Puchalski MD, Williams RV, Askovich B, et al. Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiovasc Imaging 2009; 25: 57-63.
    1. Eagle M., Bourke J, Bullock R, Gibson M, Mehta J, Giddings D, Straub V, Bushby K. Managing Duchenne muscular dystrophy-the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 2007: 17 (6):470-5. Epub 2007 May 8.
    1. Bosser G, Lucron H, Lethor JP, et al. Evidence of early impairments in both right and left ventricular inotropic reserves in children with Duchenne’s muscular dystrophy. Am J Cardiol 2004; 93:724–727.
    1. Jefferies JL, Eidem BW, Belmont JW, et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 2005; 112:2799–2804.
    1. Naruse H, Miyagi J, Arii T, et al. The relationship between clinical stage, prognosis and myocardial damage in patients with Duchenne-type muscular dystrophy: Five-year follow-up study. Ann Nucl Med 2004; 18: 203–208.
    1. Stöllberger C, Finsterer J. Can perindopril delay the onset of heart failure in Duchenne muscular dystrophy? J Am Coll Cardiol 2005; 46:1781.
    1. Guazzi, M, et al Comparison in changes of respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure due to ischemic or dilated cardiomyopathy. Am J Cardiol 1997; 80:1572-76.
    1. Gurlek A, et al. Effect of losartan on circulating TNFalpha levels and left ventricular systolic performance in patients with heart failure. J Cardiovasc Risk 2001; 8: 279
    1. Yamazaki T, et al. A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an angiotensin II receptor blocker. Int Heart J 2007; 48:715-24.
    1. Bahk T, et al. Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for prevention of experimental autoimmune myocarditis. Int J Cardiol 2008; 125:85-93.
    1. Ozdemir M, et al. Losartan Improves Heart Rate Variability and Heart Rate Turbulence in Heart Failure Due to Ischemic Cardiomyopathy. J Cardiac Fail 2007; 13:812-817.
    1. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007;13: 204-210.
    1. Spurney CF, Sali A, Guerron AD, et al. Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther 2011; 16:87-95.
    1. Bish LT, Yarchoan M, Sleeper MM, et al. Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice. PLoS One 2011; 6:e20856.
    1. Lanza GA, Dello Russo A, Giglio V, et al. Impairment of cardiac autonomic function in patients with Duchenne muscular dystrophy: Relationship to myocardial and respiratory function. Am Heart J 2001; 141:808–812.
    1. Kirschmann C, Kececioglu D, Korinthenberg R, et al. Echocardiographic and electrocardiographic findings of cardiomyopathy in Duchenne and Becker-Kiener muscular dystrophies. Pediatr Cardiol 2005; 26:66–72.
    1. Vita G, DiLeo R, DeGregorio C, et al. Cardiovascular autonomic control in Becker muscular dystrophy. J Neurol Sci 2001; 186:45–49.
    1. Akita H, Matsuoka S, Kuroda Y. Predictive electrocardiographic score for evaluating prognosis in patients with Duchenne’s muscular dystrophy. Tokushima J Exp Med 1993; 40:55–60.
    1. Lang, RM, Bierig M, Devereux RB, et al., Chanber Quantification Writing Group, American Society of Echocardiography’s Guidelines and Standared Committee, European Association of Echocardiography, Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification writing group, deverloped in conjuction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2004; 18(12): 1440-63.
    1. Nielsen JC, Lytrivi ID, Ko HH, et al.,The accuracy of echocardiographic assessment of left ventricular size in children by the 5/6 area x length (bullet) method. Echocardiogr. 2010; 27 (6); 691-5.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren